Ed Feener
Fondateur chez KALVISTA PHARMACEUTICALS, INC.
Fortune : 850 253 $ au 31/05/2024
Postes actifs de Ed Feener
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/11/2016 | - |
| Fondateur | 26/03/2004 | - | |
KalVista Pharmaceuticals Ltd.
 KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Fondateur | 01/01/2011 | - |
| Corporate Officer/Principal | 01/01/2011 | - |
Historique de carrière de Ed Feener
Anciens postes connus de Ed Feener
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Harvard Medical School | Corporate Officer/Principal | 01/07/1989 | 01/10/2016 |
Formation de Ed Feener
| Boston University | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Royaume-Uni | 2 |
| Israël | 2 |
Opérationnelle
| Founder | 2 |
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
